Sunshine Biopharma (SBFMW) Income from Continuing Operations (2011 - 2026)
Sunshine Biopharma (SBFMW) reported Income from Continuing Operations of 1243869.0 for Q1 2026, down 5.43% on a YoY basis from 1315332.16 in Q1 2025, and up 41.9% quarter-over-quarter from 2140927.0 in Q4 2025.
Sunshine Biopharma (SBFMW) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Sunshine Biopharma has reported Income from Continuing Operations for 15 years, with the latest figure at 1243869.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 5.43% year-over-year to 1243869.0; the trailing twelve-month figure through Mar 2026 stood at 6039450.0 (down 513.49% YoY), and the FY2025 full-year result was 5975352.0, down 540.47% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1243869.0, up from 2140927.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4332476.0 in Q4 2024, with the low at 23512315.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 2183125.47 across 5 years, with a median of 1236234.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 3624.47% — and 2024, when it surged 446.59%.
- Sunshine Biopharma's Income from Continuing Operations stood at 23512315.0 in 2022, then soared by 94.68% to 1250024.0 in 2023, then surged by 446.59% to 4332476.0 in 2024, then plunged by 149.42% to 2140927.0 in 2025, then jumped by 41.9% to 1243869.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1243869.0 (Q1 2026), 2140927.0 (Q4 2025), and 883820.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 197.90 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | -11.19 Mn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 52.88 Mn |
| 10 | Sunshine Biopharma | - | - | 2.18 Mn | -1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 Mn |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -883,820.00 |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -1.18 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -494,300.00 |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -1.25 Mn |
| Sep 30, 2023 | -651,482.00 |
| Jun 30, 2023 | -902,108.00 |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -23.51 Mn |
| Sep 30, 2022 | -1.46 Mn |
| Jun 30, 2022 | -538,872.00 |
| Mar 31, 2022 | -1.24 Mn |
| Dec 31, 2021 | 667,116.00 |
| Sep 30, 2021 | -4.04 Mn |
| Jun 30, 2021 | -2.88 Mn |